Epstein-Barr virus and risk of non-Hodgkin lymphoma in the cancer prevention study-II and a meta-analysis of serologic studies

Teras, Lauren R.; Rollison, Dana E.; Pawlita, Michael; Michel, Angelika; Brozy, Johannes; Sanjosé, Sílvia de; Blase, Jennifer L.; Gapstur, Susan M.

doi:10.1002/ijc.28971

Cited by 39 publications

(39 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Others have suggested that chemical or biological components of transfused blood may cause a temporary immunomodulation [30, 31], promoting lymphoma development, but this hypothesis would not explain why risks remain high many years after transfusion. Emerging evidence has suggested possible associations between viruses and some non-Hodgkin lymphoma cases, including Epstein–Barr virus [32] and again Hepatitis G virus [33, 34], and these viruses are not screened for in transfused blood.…”

Section: Discussionmentioning

confidence: 99%

Cancer risk among 21st century blood transfusion recipients

et al. 2017

View full text Add to dashboard Cite

BackgroundSome carcinogenic viruses are known to be transmissible by blood transfusion. Intensive viral screening of transfused blood now exists in most countries. In the UK, high-sensitivity nucleic acid amplification tests for hepatitis C virus were introduced in 1999 and it was thought that this would reduce, and possibly eliminate, transfusion-related liver cancer. We aimed to investigate cancer risk in recipients of blood transfusion in 2000 or after.MethodsA total of 1.3 million UK women recruited in 1998 on average were followed for hospital records of blood transfusion and for cancer registrations. After excluding women with cancer or precancerous conditions before or at the time of transfusion, Cox regression yielded adjusted relative risks of 11 site-specific cancers for women with compared to without prior blood transfusion.ResultsDuring follow up, 11 274 (0.9%) women had a first recorded transfusion in 2000 or after, and 1648 (14.6%) of them were subsequently diagnosed with cancer, a mean 6.8 years after the transfusion. In the first 5 years after transfusion there were significant excesses for most site-specific cancers examined, presumably because some had preclinical cancer. However, 5 or more years (mean 8 years) after blood transfusion, there were significant excess risks only for liver cancer (adjusted relative risk = 2.63, 95%CI 1.45–4.78) and for non-Hodgkin lymphoma (adjusted relative risk = 1.74, 1.21–2.51). When analyses were restricted to those undergoing hip or knee replacement surgery, the commonest procedure associated with transfusion, these relative risks were not materially altered.ConclusionsIn a large cohort of UK women, transfusions in the 21st century were associated with long-term increased risks of liver cancer and non-Hodgkin lymphoma. Some of these malignancies may have been caused by carcinogenic agents that are not currently screened for in transfused blood.

show abstract

Section: Discussionmentioning

confidence: 99%

Cancer risk among 21st century blood transfusion recipients

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In the current study, antibody reactivities were analyzed as dichotomous variables (seropositive vs. seronegative) consistent with their use in epidemiological studies. Algorithms used for deriving MFI cutoff values defining seropositivity have been described elsewhere (17)(18)(19)(20)(21)(22)(23)(24).…”

Section: Serological Methodsmentioning

confidence: 99%

Preanalytical Stability of Antibodies to Pathogenic Antigens

Hodgkinson

Egger

Betsou

et al. 2017

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

Serologic testing for antibodies against epitopes from pathogens is a valuable tool for investigating the relationship between infection and disease. This study comprehensively evaluates the impact of preanalytic variation on antibody seropositivities to a selected set of antigens arising from delays in processing of blood samples, preprocessing storage temperature, and vacutainer type. We assessed peripheral blood collected from 29 volunteers in four different Vacutainer types [ethylenediaminoetetraacetic acid (EDTA), acid-citrate-dextrose (ACD), lithium heparin (LH), serum separator tubes (SST)], and stored at 4°C or room temperature for 0, 1, 2, 3, 4, 5, and 6 days before processing. Multiplex serology was used to determine antibody reactivity against 35 antigens derived from human papillomaviruses, human polyomaviruses, Epstein-Barr virus, and Cohen's κ statistic was used to measure agreement on seropositivity status between samples exposed to standard and nonstandard clinical practice conditions. For samples processed without delay, κ was not associated with storage-temperature ( value range 0.23 to 0.95) or vacutainer type ( value range, 0.35-0.89). Kappa did not significantly decline with increasing delays in processing for any vacutainer-type storage temperature combination ( slope range, 0.06-1.00). Antibodies to epitopes from various pathogenic infectious agents can be measured reliably from samples stored in SST, EDTA, ACD, or LH vacutainers at either room temperature or 4°C for up to 6 days before processing. Serologic testing is robust to several preanalytic options. These findings are particularly important for epidemiologic studies recruiting participants from remote settings where sample exposure to preanalytic conditions can vary considerably. .

show abstract

“…The extent to which EBV may be associated with common NHL subtypes, such as those that account for most of the NHL cases in population‐based cohorts, is still unresolved. A recent meta‐analysis that evaluated population‐based serologic studies of EBV and risk of NHL, all of which were conducted in Western populations, reported an increased risk of NHL associated with higher antibodies to the early antigen diffuse (EA‐D) and viral capsid antigen (VCA) . The relationship between some other herpesviruses, such as human herpesvirus‐6 and −7 (HHV‐6; HHV‐7) and cytomegalovirus (CMV), and NHL risk in prospective studies is not well understood and requires further evaluation.…”

mentioning

confidence: 99%

Serologic markers of viral infection and risk of non‐Hodgkin lymphoma: A pooled study of three prospective cohorts in China and Singapore

Bassig

Willhauck‐Fleckenstein

Shu

et al. 2018

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Incidence rates of non-Hodgkin lymphoma (NHL) and distributions of certain viruses differ between East Asian and Western populations. There are limited data on associations between serologic markers of multiple viral infections in pre-diagnostic blood and NHL risk in East Asians. We conducted a nested case-control study of 214 NHL cases and 214 matched controls from three population-based prospective cohorts in Shanghai and Singapore. Antibodies against antigens from herpesviruses, Hepatitis B (HBV) and C (HCV) virus and polyomaviruses were measured in plasma or serum using fluorescent bead-based multiplex assays. Conditional logistic regression was used to evaluate associations between antibody levels and NHL risk. An increased risk of NHL was observed for higher compared to lower EA-D (Odds Ratio (OR) = 2.04, 95% Confidence Interval (CI) = 1.10-3.81; p = 0.005) and ZEBRA (OR = 2.17, 95% CI = 0.96-4.89; p = 0.008) Epstein-Barr Virus (EBV) antibodies, as well as for antibody seropositivity against the IE1A human herpesvirus-6 (HHV-6) antigen (OR = 1.85, 95% CI = 1.04-3.29). An increased NHL risk was also observed for higher compared to lower antibodies against the HBV-HBc and HBe antigens. An increased risk of NHL in relation to EBV and HBV infection in East Asians is consistent with findings in several studies of Western populations, suggesting similar viral risk factors for NHL in these diverse populations with distinct patterns of NHL. The association between HHV-6 antibodies and NHL has not previously been reported in a prospective study in this population and will require replication.

show abstract

Epstein-Barr virus and risk of non-Hodgkin lymphoma in the cancer prevention study-II and a meta-analysis of serologic studies

Cited by 39 publications

References 23 publications

Cancer risk among 21st century blood transfusion recipients

Cancer risk among 21st century blood transfusion recipients

Preanalytical Stability of Antibodies to Pathogenic Antigens

Serologic markers of viral infection and risk of non‐Hodgkin lymphoma: A pooled study of three prospective cohorts in China and Singapore

Contact Info

Product

Resources

About